Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review.
Scand J Rheumatol Suppl 1998;107:97-102 (ISSN: 0301-3847) Harris EN; Pierangeli SS Academic Affairs, Morehouse School of Medicine, Atlanta, GA 30310-1495, USA.
Although experience is still limited, intravenous immunoglobulin therapy for recurrent pregnancy loss in the Antiphospholipid Syndrome (APS) may represent a significant advance. APS was widely recognized only fifteen years ago. Pregnancy loss and thrombosis are the prominent clinical features. Initially, prednisone was used for treatment of pregnancy loss, but matemal and fetal complications stimulated searches for alternative therapy. Subcutaneous heparin and low dose aspirin was next utilized, but although efficacious, there is still a 30% failure rate, and intrauterine growth retardation, prematurity, and pre-eclampsia are relatively frequent. In the late 1980’s, there were a number of case reports of successful pregnancy outcomes after treatment with intravenous immunoglobulin (IVIg) but regimens differed. Series from two centers have confirmed these initial findings and treatment regimens have become more consistent. Both centers have reported success with doses of 400 mg/kg/day for 5 days or 1 g/kg/day for two days each month initiated during the first or early second trimester. Success rates of 70-100% have been reported, and complications such as pre-eclampsia, intrauterine growth retardation, and premature births appear reduced, when compared to prednisone and low dose aspirin or heparin and low dose aspirin. Several patients who were treated with IVIg also received heparin, making it uncertain whether heparin may also need to be added to IVIg. Intravenous immunoglobulin is safe, but expensive. Despite its expense, if IVIG is shown to markedly decrease matemal and fetal morbidity, it may be the logical treatment of choice to prevent pregnancy loss in APS.
If you value this service, kindly consider a donation to the Canadian Breastfeeding Foundation (registered charity). Earmark the donation for the International Breastfeeding Centre (Newman Breastfeeding Clinic) and/or the Goldfarb Breastfeeding Program.
Donate online: canadahelps.orgDonate by mail: Canadian Breastfeeding Foundation, 5890 Monkland Ave, Suite 16, Montreal, Quebec, Canada H4A 1G2.
© 2002-2019 Lenore Goldfarb, PhD, CCC, IBCLC, ALC and contributing authors to AskLenore.info. All rights reserved.
Disclaimer: The information provided on this website is for general informational purposes only and does not constitute medical advice. You should not rely on this information as a substitute for, nor does it replace, professional medical advice, diagnosis, or treatment. If you have any specific questions or concerns about any health issue, you should consult with a qualified healthcare provider.
The AskLenore administration is not affiliated with, nor sponsored by, nor do we sell or receive any commissions or incentives from, any of the products or services that we link to on this website. Therefore, we are not responsible for the accuracy, quality, availability, or suitability of said products or services. You should always do your own research and due diligence before purchasing or using any product or service that we link to on this website.
The views and opinions expressed on the message boards are those of the authors and do not necessarily reflect the official policy or position of asklenore.info. Any content provided by our users are of their opinion and are not intended to malign any religion, ethnic group, club, organization, company, individual or anyone or anything.